Skip to main content
MEDICALSYSTEM BIOTECHNOLOGY CO., LTD logo

MEDICALSYSTEM BIOTECHNOLOGY CO., LTD — Investor Relations & Filings

Ticker · 300439 ISIN · CNE100001Z25 LEI · 3003007XTAWFVR8ASC23 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,715 across all filing types
Latest filing 2024-03-14 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300439

About MEDICALSYSTEM BIOTECHNOLOGY CO., LTD

https://www.nbmksw.com

MedicalSystem Biotechnology Co., Ltd. specializes in the research, development, production, and distribution of in vitro diagnostic (IVD) products. The company offers a comprehensive portfolio that includes biochemical reagents, chemiluminescence immunoassay systems, molecular diagnostic kits, and point-of-care testing (POCT) solutions. Its product line covers a wide range of clinical applications such as liver function, kidney function, blood lipids, and cardiovascular markers. MedicalSystem is recognized for its integrated business model, which combines the manufacturing of high-quality diagnostic instruments with a vast array of compatible reagents. Additionally, the company provides third-party medical laboratory services to healthcare institutions. By focusing on technological innovation and standardized production, MedicalSystem supports clinical laboratories in achieving accurate and efficient diagnostic results for improved patient care.

Recent filings

Filing Released Lang Actions
关于使用部分闲置募集资金暂时补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from 美康生物科技股份有限公司 regarding the use of part of idle raised funds to temporarily supplement working capital. It details the board and supervisory committee meetings approving the use of idle raised funds, the amount involved, the purpose, and compliance with regulatory requirements. It references prior approvals, regulatory filings, and the company's fundraising details but does not contain financial statements or detailed financial performance data. The document is a formal disclosure about a financing and capital management decision rather than a full financial report or audit. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length and content confirm it is not a brief announcement or a report publication notice, but a substantive update on capital use.
2024-03-14 Chinese
第五届董事会第四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the fifth board of directors' fourth meeting of Meikang Biotechnology Co., Ltd. It details the meeting date, attendance, agenda items, voting results, and references to regulatory compliance and disclosures. The content focuses on board decisions regarding the use of idle raised funds, cash management, and related party transactions. There is no financial data, earnings information, or detailed report content. The document is a board meeting resolution announcement, which fits the category of Board/Management Information (MANG). The document length is short (1849 characters), and it is not a report publication announcement or certification. Therefore, the classification is MANG with high confidence.
2024-03-14 Chinese
中天国富证券有限公司关于美康生物科技股份有限公司使用部分闲置募集资金进行现金管理的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed report from a sponsoring securities company (中天国富证券有限公司) regarding the use of idle raised funds by 美康生物科技股份有限公司 for cash management. It includes specifics about the raised funds, usage, idle reasons, previous and current cash management approvals, risk controls, and board and supervisory approvals. The document references regulatory guidelines and includes formal opinions from the sponsor. It is not an announcement of a report but a substantive regulatory compliance and supervisory report related to the use of raised funds. This fits the category of a Regulatory Filing (RNS) because it is a compliance and supervisory disclosure related to fundraising and fund usage, not a full annual or interim financial report, nor a simple announcement or presentation. The document length and content confirm it is not a brief announcement or certification but a detailed regulatory disclosure.
2024-03-14 Chinese
关于归还用于暂时补充流动资金的闲置募集资金的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by 美康生物科技股份有限公司 regarding the return of temporarily used idle raised funds that were used to supplement working capital. It details the board resolutions, compliance with regulatory requirements, and the completion of the return of funds. The document is short (1030 characters) and focuses on a specific financing/capital management event rather than a full financial report or audit. It does not contain financial statements or detailed financial analysis. Therefore, it fits best under Capital/Financing Update (CAP) as it updates on the company's use and return of raised capital funds.
2024-03-14 Chinese
中天国富证券有限公司关于美康生物科技股份有限公司使用部分闲置募集资金暂时补充流动资金的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from a sponsoring securities company (中天国富证券有限公司) regarding the use of idle raised funds by 美康生物科技股份有限公司. It includes specifics about the raised funds, their usage, idle reasons, cash management, and approvals by the board and supervisory committee. The document references regulatory guidelines and approvals from the China Securities Regulatory Commission and Shenzhen Stock Exchange rules. It is a formal verification and opinion report on the temporary use of idle raised funds to supplement working capital. The document is about the use and management of raised funds, not a general financial report, earnings release, or announcement of voting results. It is not a short announcement but a substantive report with detailed financial and regulatory compliance information. This fits the category of Audit Report / Information (AR), which includes applied accounting principles and regulatory compliance reports related to raised funds and their management, but is not a full annual or interim report. Q1 2024
2024-03-14 Chinese
第五届监事会第三次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of 美康生物科技股份有限公司 regarding decisions made in their third meeting of the fifth session. It includes approvals on the use of idle raised funds for temporary liquidity and cash management, and forecasts of related party transactions for 2024. The document is a formal announcement of meeting resolutions and voting results, not a full financial report or detailed management discussion. It does not contain financial statements or detailed financial analysis. The document length is short (1847 characters) and it is primarily a meeting resolution announcement. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance document rather than a specific report type like Annual Report or Interim Report.
2024-03-14 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.